Mometasone Furoate Market Analysis

  • Report ID: 5507
  • Published Date: Jan 03, 2025
  • Report Format: PDF, PPT

Mometasone Furoate Market Analysis

 Route of administration (Topical, Nasal, Oral)

In mometasone furoate market, topical segment is poised to account for around 42% share by 2037. The reason behind this lucrative growth is impelled by the surge in the growth of skin conditions like eczema, psoriasis, and dermatitis worldwide. According to a report, about 223 million people worldwide, including 43 million children and young adults, suffered from atopic dermatitis in 2022. Mometasone, in the form of creams, ointments, and lotions, has shown great efficacy in managing these conditions, which leads to its popularity among healthcare professionals and patients.

In addition, advancements in formulation technology have improved the delivery and absorption of mometasone through the skin, enhancing its efficacy. Therefore, these innovations have led to the expansion of the topical segment.

Indication (Allergic Rhinitis, Inflammatory Skin Disorders, Asthma)

The allergic rhinitis segment in mometasone furoate market is set to garner a notable share. It is likely to remain the second largest segment, led by the substantial growth in quicker and higher-quality diagnostic techniques. In addition, the enormous financial burden on society due to disability and early death raises costs for prescription drugs, direct health care, and indirect costs associated with lost productivity.

Treatment for allergic asthma is often required in conjunction with perennial allergic rhinitis. The market size expansion for treatments for allergic rhinitis is also being impacted by this illness worldwide. Moreover, mometasone nasal spray is frequently recommended to help reduce allergic rhinitis symptoms. The expansion of this market size can be attributed to mometasone's efficacy in treating allergic rhinitis.

Our in-depth analysis of the global market includes the following segments: 

            Route of administration

  • Topical
  • Nasal
  • Oral

            Indication

  • Allergic Rhinitis
  • Inflammatory Skin Disorders
  • Asthma

            Dosage form

  • Nasal Spray
  • Cream
  • Ointment
  • Inhalers

            Distribution channel

  • Hospital
  • Retail
  • Online
Get more information on this report: Request Free Sample PDF

Browse Key Market Insights with Data Illustration:


Author Credits:  Rajrani Baghel


  • Report ID: 5507
  • Published Date: Jan 03, 2025
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of mometasone furoate is evaluated at USD 1.14 billion.

The mometasone furoate market size was over USD 1.07 billion in 2024 and is poised to exceed USD 2.64 billion by 2037, growing at over 7.2% CAGR during the forecast period i.e., between 2025-2037. The market growth is owing to rising uncontrolled asthmatic conditions, which affect both children and adults.

North America industry is likely to hold largest revenue share of 47% by 2037, propelled by surge in the number of awareness campaigns regarding psoriasis, coupled with the high prevalence of skin conditions like eczema in the region.

The major players in the market are Bausch Health Companies Inc., Glenmark Pharmaceuticals Limited, Vetoquinol USA, AstraZeneca plc, Intersect ENT, Hikma Pharmaceuticals, Medlab Pharmaceuticals Private Limited, AdvaCare Pharma, Dermocare Laboratories, Taro Pharmaceutical Industries Ltd., Kyorin Remedio Co., Ltd, Teikoku Seiyaku Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Takeda Pharmaceuticals., and others.
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample